Methamphetamine dependence: Consequences and complications;Dépendance à la méthamphétamine: de nombreuses conséquences et complications

Presse Medicale

Volumn 39, Issue 12, 2010, Pages 1246-1253

  Karila, Laurent ^a,b,c   Petit, Aymeric ^d   Cottencin, Olivier ^e   Reynaud, Michel ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c DIF   (France)

^d BICHAT HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHAMPHETAMINE;

ADVERSE OUTCOME; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; DRUG ABUSE; DRUG DEPENDENCE; HUMAN; INFECTION COMPLICATION; LUNG DISEASE; MOOD DISORDER; PSYCHOSIS; SHORT SURVEY; SOCIAL INTERACTION; TOOTH DISEASE;

AMPHETAMINE-RELATED DISORDERS; CROSS-CULTURAL COMPARISON; CROSS-SECTIONAL STUDIES; FRANCE; HUMANS; METHAMPHETAMINE; RISK FACTORS; STREET DRUGS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 78649860758     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.09.003     Document Type: Short Survey

References (85)

1. EMCDDA. Methamphetamine. A European Union perspective in the global context Luxembourg: Office for Official Publications of the European Communities 2009. 30 pp.
2. Parsons J.T., Grov C., Kelly B.C. Club drug use and dependence among young adults recruited through time-space sampling. Public Health Rep 2009, 124:246-254.
3. EMCDDA. Annual report on the state of the drugs problem in Europe; 2009.
4. Darke S., Kaye S., McKetin R., Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008, 27:253-262.
5. McKetin R, Kelly E, McLaren J, Proudfoot H. Impaired physical health among methamphetamine users in comparison with the general population: the role of methamphetamine dependence and opioid use. Drug Alcohol Rev 2008:27482-9.
6. Karila L., Weinstein A., Aubin H.J., Benyamina A., Reynaud M., Batki S.L. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 2010, 69:578-592.
7. Lee N.K., Rawson R.A. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 2008, 27:309-317.
8. Vocci F.J., Montoya I.D. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry 2009, 22:263-268.
9. Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction 2009, 104:1085-1099.
10. Nakagawa T., Kaneko S. Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine 3,4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N,N-diisopropyltryptamine (foxy). J Pharmacol Sci 2008, 106:2-8.
11. Vergo S., Johansen J.L., Leist M., Lotharius J. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res 2007, 1185:18-32.
12. McCann U.D., Wong D.F., Yokoi F., Villemagne V., Dannals R.F., Ricaurte G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998, 18:8417-8422.
13. Pereira F.C., Lourenco E., Milhazes N., Morgadinho T., Ribeiro C.F., Ali S.F., et al. Methamphetamine, morphine, and their combination: acute changes in striatal dopaminergic transmission evaluated by microdialysis in awake rats. Ann N Y Acad Sci 2006, 1074:160-173.
14. Kinner S.A., Degenhardt L. Crystal methamphetamine smoking among regular ecstasy users in Australia: increases in use and associations with harm. Drug Alcohol Rev 2008, 27:292-300.
15. Freese T.E., Obert J., Dickow A., Cohen J., Lord R.H. Methamphetamine abuse: issues for special populations. J Psychoactive Drugs 2000, 32:177-182.
16. Reback C.J., Shoptaw S., Grella C.E. Methamphetamine use trends among street-recruited gay and bisexual males, from 1999 to 2007. J Urban Health 2008, 85:874-879.
17. De La Garza 2nd R., Zorick T., Heinzerling K.G., Nusinowitz S., London E.D., Shoptaw S., et al. The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. Pharmacol Biochem Behav 2009, 94:186-193.
18. Haas C., Karila L., Lowenstein W. Cocaine and crack addiction: a growing public health problem. Bull Acad Natl Med 2009, 193:947-962. [discussion 962-3].
19. Huff C. Crystal crush. Hosp Health Netw 2006, 80:59-64.
20. Winslow B.T., Voorhees K.I., Pehl K.A. Methamphetamine abuse. Am Fam Physician 2007, 76:1169-1174.
21. Greene S.L., Kerr F., Braitberg G. Review article: amphetamines and related drugs of abuse. Emerg Med Australas 2008, 20:391-402.
22. McKetin R., Kelly E., McLaren J. The relationship between crystalline methamphetamine use and methamphetamine dependence. Drug Alcohol Depend 2006, 85:198-204.
23. Ling W., Rawson R., Shoptaw S. Management of methamphetamine abuse and dependence. Curr Psychiatry Rep 2006, 8:345-354.
24. McGregor C., Srisurapanont M., Jittiwutikarn J., Laobhripatr S., Wongtan T., White J.M. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005, 100:1320-1329.
25. Newton T.F., Kalechstein A.D., Duran S., Vansluis N., Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict 2004, 13:248-255.
26. Galloway G.P., Singleton E.G. How long does craving predict use of methamphetamine? Assessment of use one to seven weeks after the assessment of craving: Craving and ongoing methamphetamine use. Subst Abuse 2009, 1:63-79.
27. Peck J.A., Shoptaw S., Rotheram-Fuller E., Reback C.J., Bierman B. HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men. J Addict Dis 2005, 24:115-132.
28. Hong R., Matsuyama E., Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991, 265:1152-1154.
29. Haning W., Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction 2007, 102:70-75.
30. Yu Q., Larson D.F., Watson R.R. Heart disease, methamphetamine and AIDS. Life Sci 2003, 73:129-140.
31. Benyamina A., Saffroy R., Blecha L., Pham P., Karila L., Debuire B., et al. Association between MTHFR 677C-T polymorphism and alcohol dependence according to Lesch and Babor typology. Addict Biol 2009, 14:503-505.
32. Kaye S., McKetin R., Duflou J., Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007, 102:1204-1211.
33. Swalwell C.I., Davis G.G. Methamphetamine as a risk factor for acute aortic dissection. J Forensic Sci 1999, 44:23-26.
34. Margolis M.T., Newton T.H. Methamphetamine (speed) arteritis. Neuroradiology 1971, 2:179-182.
35. Lynch J., House M.A. Cardiovascular effects of methamphetamine. J Cardiovasc Nurs 1992, 6:12-18.
36. Ho E.L., Josephson S.A., Lee H.S., Smith W.S. Cerebrovascular complications of methamphetamine abuse. Neurocrit Care 2009, 10:295-305.
37. Perez Jr.J.A., Arsura E.L., Strategos S. Methamphetamine-related stroke: four cases. J Emerg Med 1999, 17:469-471.
38. Thompson C.A. Pulmonary arterial hypertension seen in methamphetamine abusers. Am J Health Syst Pharm 2008, 65:1109-1110.
39. Schaiberger P.H., Kennedy T.C., Miller F.C., Gal J., Petty T.L. Pulmonary hypertension associated with long-term inhalation of crank methamphetamine. Chest 1993, 104:614-616.
40. Nestor T.A., Tamamoto W.I., Kam T.H., Schultz T. Crystal methamphetamine-induced acute pulmonary edema: a case report. Hawaii Med J 1989, 48:457-460.
41. Tashkin D.P. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med 2001, 7:43-61.
42. Lee B., London E.D., Poldrack R.A., Farahi J., Nacca A., Monterosso J.R., et al. Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 2009, 29:14734-14740.
43. Shoptaw S., Reback C.J. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction 2007, 102(Suppl 1):130-135.
44. Rawson R.A., Gonzales R., Pearce V., Ang A., Marinelli-Casey P., Brummer J. Methamphetamine dependence and human immunodeficiency virus risk behavior. J Subst Abuse Treat 2008, 35:279-284.
45. Cherner M., Letendre S., Heaton R.K., Durelle J., Marquie-Beck J., Gragg B., et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005, 64:1343-1347.
46. Gonzales R., Marinelli-Casey P., Hillhouse M., Hunter J., Rawson R.A., Mooney L., et al. Hepatitis A and B infection among methamphetamine-dependent users. J Subst Abuse Treat 2008, 35:351-352.
47. Bergstrom K.G. Cutaneous clues to drug addiction. J Drugs Dermatol 2008, 7:303-305.
48. Spann M.D., McGwin Jr.G., Kerby J.D., George R.L., Dunn S., Rue 3rd L.W., et al. Characteristics of burn patients injured in methamphetamine laboratory explosions. J Burn Care Res 2006, 27:496-501.
49. Hamamoto D.T., Rhodus N.L. Methamphetamine abuse and dentistry. Oral Dis 2009, 15:27-37.
50. Heng C.K., Badner V.M., Schiop L.A. Meth mouth. N Y State Dent J 2008, 74:50-51.
51. Lan K.C., Lin Y.F., Yu F.C., Lin C.S., Chu P. Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc 1998, 97:528-533.
52. Guilarte T.R. Is methamphetamine abuse a risk factor in parkinsonism?. Neurotoxicology 2001, 22:725-731.
53. Hazin R., Cadet J.L., Kahook M.Y., Saed D. Ocular manifestations of crystal methamphetamine use. Neurotox Res 2009, 15:187-191.
54. Kim Y.T., Lee S.W., Kwon D.H., Seo J.H., Ahn B.C., Lee J. Dose-dependent frontal hypometabolism on FDG-PET in methamphetamine abusers. J Psychiatr Res 2009, 43:1166-1170.
55. Scott J.C., Woods S.P., Matt G.E., Meyer R.A., Heaton R.K., Atkinson J.H., et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 2007, 17:275-297.
56. Baicy K., London E.D. Corticolimbic dysregulation and chronic methamphetamine abuse. Addiction 2007, 102:5-15.
57. Nordahl T.E., Salo R., Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci 2003, 15:317-325.
58. van der Plas EA, Crone EA, van den Wildenberg WP, Tranel D, Bechara A. Executive control deficits in substance-dependent individuals: a comparison of alcohol, cocaine, and methamphetamine and of men and women. J Clin Exp Neuropsychol 2008:1-14.
59. Rendell P.G., Mazur M., Henry J.D. Prospective memory impairment in former users of methamphetamine. Psychopharmacology (Berl) 2009, 203:609-616.
60. Salo R., Nordahl T.E., Galloway G.P., Moore C.D., Waters C., Leamon M.H. Drug abstinence and cognitive control in methamphetamine-dependent individuals. J Subst Abuse Treat 2009, 37:292-297.
61. Tomiyama G. Chronic schizophrenia-like states in methamphetamine psychosis. Jpn J Psychiatry Neurol 1990, 44:531-539.
62. Dore G., Sweeting M. Drug-induced psychosis associated with crystalline methamphetamine. Australas Psychiatry 2006, 14:86-89.
63. Lapworth K., Dawe S., Davis P., Kavanagh D., Young R., Saunders J. Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users. Addict Behav 2009, 34:380-385.
64. McKetin R., McLaren J., Lubman D.I., Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006, 101:1473-1478.
65. Barr A.M., Panenka W.J., MacEwan G.W., Thornton A.E., Lang D.J., Honer W.G., Lecomte T. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006, 31:301-313.
66. Glasner-Edwards S., Mooney L.J., Marinelli-Casey P., Hillhouse M., Ang A., Rawson R. Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat 2008, 35:445-450.
67. Shoptaw S., Peck J., Reback C.J., Rotheram-Fuller E. Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment. J Psychoactive Drugs 2003, 35:161-168.
68. Lazarou E.E. Manufacturing methamphetamine: medical-psychiatric complications of an illegal act. J Psychiatr Pract 2008, 14:241-245.
69. Semple SJ, Zians J, Strathdee SA, Patterson TL. Psychosocial and behavioral correlates of depressed mood among female methamphetamine users. J Psychoactive Drugs 2007;Suppl 4:353-66.
70. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001, 158:1206-1214.
71. Kalechstein A.D., Newton T.F., Longshore D., Anglin M.D., van Gorp W.G., Gawin F.H. Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci 2000, 12:480-484.
72. Bousman C.A., Cherner M., Ake C., Letendre S., Atkinson J.H., Patterson T.L., et al. Negative mood and sexual behavior among non-monogamous men who have sex with men in the context of methamphetamine and HIV. J Affect Disord 2009, 119:84-91.
73. Wohl A.R., Frye D.M., Johnson D.F. Demographic characteristics and sexual behaviors associated with methamphetamine use among MSM and non-MSM diagnosed with AIDS in Los Angeles County. AIDS Behav 2008, 12:705-712.
74. Mansergh G., Shouse R.L., Marks G., Guzman R., Rader M., Buchbinder S., et al. Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men. Sex Transm Infect 2006, 82:131-134.
75. Brewer D.D., Golden M.R., Handsfield H.H. Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy. Sex Transm Dis 2006, 33:250-255.
76. Semple S.J., Zians J., Grant I., Patterson T.L. Sexual compulsivity in a sample of HIV-positive methamphetamine-using gay and bisexual men. AIDS Behav 2006, 10:587-598.
77. Colfax G., Coates T.J., Husnik M.J., Huang Y., Buchbinder S., Koblin B., et al. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men. J Urban Health 2005, 82:62-70.
78. Newton T.F., De La Garza R., 2nd, Kalechstein A.D., Tziortzis D., Jacobsen CA Theories of addiction: methamphetamine users' explanations for continuing drug use and relapse. Am J Addict 2009, 18:294-300.
79. Kaye S., Darke S., Duflou J., McKetin R. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction 2008, 103:1353-1360.
80. Gold M.S., Graham N.A., Kobeissy F.H., Pepine C.J., Goldberger B.A. Speed, cocaine, and other psychostimulants death rates. Am J Cardiol 2007, 100:1184.
81. Drummer O.H., Gerostamoulos J., Batziris H., Chu M., Caplehorn J.R., Robertson M.D., et al. The incidence of drugs in drivers killed in Australian road traffic crashes. Forensic Sci Int 2003, 134:154-162.
82. Raikos N., Tsoukali H., Psaroulis D., Vassiliadis N., Tsoungas M., Njau S.N. Amphetamine derivative related deaths in northern Greece. Forensic Sci Int 2002, 128:31-34.
83. Karila L., Weinstein A., Benyamina A., Coscas S., Leroy C., Noble F., et al. Pharmacothérapies actuelles et immunothérapie dans l'addiction à la cocaïne. Presse Med 2008, 37:689-698.
84. Karila L., Berlin I., Benyamina A., Reynaud M. Psychotic symptoms following buprenorphine withdrawal. Am J Psychiatry 2008, 165:400-401.
85. Vocci F.J., Appel N.M. Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 2007, 102(Suppl 1):96-106.